TENAYA THERAPEUTICS INC (TNYA) Stock Price & Overview
NASDAQ:TNYA • US87990A1060
Current stock price
The current stock price of TNYA is 0.6946 USD. Today TNYA is up by 2%. In the past month the price decreased by -15.22%. In the past year, price increased by 39.25%.
TNYA Key Statistics
- Market Cap
- 150.728M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.62
- Dividend Yield
- N/A
TNYA Stock Performance
TNYA Stock Chart
TNYA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to TNYA. When comparing the yearly performance of all stocks, TNYA is one of the better performing stocks in the market, outperforming 70.77% of all stocks.
TNYA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TNYA. While TNYA has a great health rating, there are worries on its profitability.
TNYA Earnings
TNYA Forecast & Estimates
14 analysts have analysed TNYA and the average price target is 10.2 USD. This implies a price increase of 1368.47% is expected in the next year compared to the current price of 0.6946.
TNYA Groups
Sector & Classification
TNYA Financial Highlights
Over the last trailing twelve months TNYA reported a non-GAAP Earnings per Share(EPS) of -0.62. The EPS increased by 53.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.66% | ||
| ROE | -73.5% | ||
| Debt/Equity | 0 |
TNYA Ownership
TNYA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TNYA
Company Profile
Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. The company is headquartered in South San Francisco, California and currently employs 70 full-time employees. The company went IPO on 2021-07-30. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.
Company Info
IPO: 2021-07-30
TENAYA THERAPEUTICS INC
171 Oyster Point Blvd., Suite 500
South San Francisco CALIFORNIA US
CEO: Faraz Ali
Employees: 70
Phone: 14158652066
TENAYA THERAPEUTICS INC / TNYA FAQ
Can you describe the business of TENAYA THERAPEUTICS INC?
Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. The company is headquartered in South San Francisco, California and currently employs 70 full-time employees. The company went IPO on 2021-07-30. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.
What is the stock price of TENAYA THERAPEUTICS INC today?
The current stock price of TNYA is 0.6946 USD. The price increased by 2% in the last trading session.
What is the dividend status of TENAYA THERAPEUTICS INC?
TNYA does not pay a dividend.
How is the ChartMill rating for TENAYA THERAPEUTICS INC?
TNYA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the employee count for TNYA stock?
TENAYA THERAPEUTICS INC (TNYA) currently has 70 employees.
What is the ownership structure of TENAYA THERAPEUTICS INC (TNYA)?
You can find the ownership structure of TENAYA THERAPEUTICS INC (TNYA) on the Ownership tab.